13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Chengdu Institute of Biological Products)

Primary objective: To evaluate the safety of 13-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) to 59 years old. Secondary objective: To preliminarily evaluate the immunogenicity of 13-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) to 5 years old according to the corresponding basic immunization schedule. Exploratory objective: To explore the immunogenicity of 13-valent pneumococcal polysaccharide conjugate vaccine in booster immunization in healthy infants and young children aged 2 months (minimum 6 weeks) to 11 months.